DK0895988T3 - Arylsulfonylaminohydroxamsyrederivater - Google Patents

Arylsulfonylaminohydroxamsyrederivater

Info

Publication number
DK0895988T3
DK0895988T3 DK98305959T DK98305959T DK0895988T3 DK 0895988 T3 DK0895988 T3 DK 0895988T3 DK 98305959 T DK98305959 T DK 98305959T DK 98305959 T DK98305959 T DK 98305959T DK 0895988 T3 DK0895988 T3 DK 0895988T3
Authority
DK
Denmark
Prior art keywords
aryl
hydroxamic acid
arylsulfonylamino hydroxamic
angiogenisis
occular
Prior art date
Application number
DK98305959T
Other languages
Danish (da)
English (en)
Inventor
Ralph Pelton Robinson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK0895988T3 publication Critical patent/DK0895988T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK98305959T 1997-08-08 1998-07-27 Arylsulfonylaminohydroxamsyrederivater DK0895988T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5520897P 1997-08-08 1997-08-08

Publications (1)

Publication Number Publication Date
DK0895988T3 true DK0895988T3 (da) 2002-09-09

Family

ID=21996365

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98305959T DK0895988T3 (da) 1997-08-08 1998-07-27 Arylsulfonylaminohydroxamsyrederivater

Country Status (9)

Country Link
EP (1) EP0895988B1 (fr)
JP (1) JPH11116549A (fr)
AT (1) ATE217863T1 (fr)
BR (1) BR9803128A (fr)
CA (1) CA2244501C (fr)
DE (1) DE69805473T2 (fr)
DK (1) DK0895988T3 (fr)
ES (1) ES2176913T3 (fr)
PT (1) PT895988E (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8469301A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimientos para la preparacion de acidos hidroxamicos.
PA8469601A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimiento para alquilar sulfonamidas impedidas estericamente
GT199900044A (es) * 1998-04-10 2000-09-14 Procedimientos para preparar haluros de fenoxifenilsulfonilo.
AU3196300A (en) * 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
DE60003863T2 (de) * 1999-03-31 2004-04-22 Pfizer Products Inc., Groton Dioxocyclopentylhydroxamsäure
IL138686A0 (en) * 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
WO2001070693A2 (fr) 2000-03-21 2001-09-27 The Procter & Gamble Company Inhibiteurs de metalloproteases d'acide difluorobutyrique
NZ520657A (en) 2000-03-21 2004-11-26 Procter & Gamble Heterocyclic side chain containing, N-substituted metalloprotease inhibitors
CN1366524A (zh) * 2000-04-07 2002-08-28 三星电子株式会社 磺胺衍生物作为基质金属蛋白酶抑制剂
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
AU2002256672A1 (en) * 2001-03-14 2002-09-24 Novartis Ag Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors.
EP2295081B1 (fr) 2001-06-26 2018-10-31 Amgen Inc. Anticorps OPGL
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
DE60231425D1 (de) * 2001-11-13 2009-04-16 Shiseido Co Ltd Azabicycloverbindung, matrixmetallproteaseinhibitor und zubereitung für haut
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
WO2003055851A1 (fr) 2001-12-27 2003-07-10 Sumitomo Pharmaceuticals Company, Limited Derives d'acide hydroxamique et inhibiteur des mmp contenant ces derniers en tant que substance active
WO2004060911A2 (fr) 2002-12-30 2004-07-22 Amgen Inc. Polytherapie a facteurs costimulants
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
RU2006125441A (ru) 2003-12-15 2008-01-27 Джапан Тобакко Инк. (Jp) Производные циклопропана и их фармацевтическое применение
WO2005058808A1 (fr) * 2003-12-15 2005-06-30 Japan Tobacco Inc. Composes de n-sulfonylaminocyclopropane n-substitue et leur utilisation pharmaceutique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2193691A1 (fr) * 1994-06-22 1995-12-28 Andrew Miller Inhibiteurs de metalloproteinases
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
KR20000068248A (ko) * 1996-08-23 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐아미노 하이드록삼산 유도체

Also Published As

Publication number Publication date
EP0895988A1 (fr) 1999-02-10
EP0895988B1 (fr) 2002-05-22
DE69805473T2 (de) 2003-01-16
ES2176913T3 (es) 2002-12-01
JPH11116549A (ja) 1999-04-27
CA2244501C (fr) 2003-03-18
ATE217863T1 (de) 2002-06-15
BR9803128A (pt) 2000-05-02
PT895988E (pt) 2002-09-30
DE69805473D1 (de) 2002-06-27
CA2244501A1 (fr) 1999-02-08

Similar Documents

Publication Publication Date Title
DK0895988T3 (da) Arylsulfonylaminohydroxamsyrederivater
CA2214720A1 (fr) Derives de l'acide arylsulfonylamino hydroxamique
EP0818442A3 (fr) Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs
ATE223215T1 (de) Inhibitoren der fettsäuresynthese als antimikrobielle mittel
EA199900139A1 (ru) Производные арилсульфониламиногидроксамовой кислоты
NZ330922A (en) Hydroxamic acid derivatives substituted by a series of 2-pyrrolidinones, hydantoins, and pyrazolidinones for use with the treatment of diseases related to connective tissue degradation
MY121754A (en) Arylsulfonylamino hydroxamic acid derivatives
FR2744010B1 (fr) Procede de fabrication d'implants osseux
NO920702L (no) Hydroksaminsyrebaserte kollagenaseinhibitorer
GB2290543B (en) Hydroxamic acid derivatives as metalloproteinase inhibitors
PT900211E (pt) Tiadiazolil(tio)ureias uteis como inibidores de metaloproteases com matriz
CA2340138A1 (fr) Composes hydroxamides d'acide 2-oxo-imidazolidine-4-carboxylique inhibiteurs de la metalloproteinase matricielle
CA2254731A1 (fr) Inhibition des metalloproteases matricielles par les acides 2-substitues-4-(4-phenylesubstitue)-4-oxobutyriques
DE60039601D1 (de) Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit
WO2000015208A3 (fr) Nouvelle utilisation
DK0826681T3 (da) Epoxyravsyrederivater
CA2253796A1 (fr) Inhibition de metalloproteases matricielles par des composes contenant de l'acetylene
TW363056B (en) Inhibition of matrix metalloproteases by substituted phenethyl compounds
AU2723192A (en) Thiadiazinone
WO2001082911A3 (fr) Traitement d'etats pathologiques influences par l'action de metalloprotease de matrice (mmp) au moyen de clioquinol
TNSN05067A1 (en) Acetyl 2-hydroxy- 1,3 diaminoalkanes
UA35749A (uk) Спосіб лікування карієсу
CA2244903A1 (fr) Nouveaux derives d'acide hydroxamique utilises dans le traitement de maladies liees a une degradation des tissus conjonctifs
TH33716A (th) อนุพันธ์ไฮดรอกแซมิกแอซิดชนิดใหม่ที่ใช้ประโยชน์สำหรับรักษาโรคที่เกี่ยวข้องกับการสลายตัวของเนื้อเยื่อยึดต่อ
ID21321A (id) Senyawa-senyawa betha-laktam untuk pengobatan penyakit infeksi disebabkan mikroorganisme penghasil betha-laktamase